Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.

Wu G, Qin XQ, Guo JJ, Li TY, Chen JH.

Int J Clin Exp Pathol. 2014 Mar 15;7(4):1449-58. eCollection 2014.

2.

Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell.

Xu CZ, Shi RJ, Chen D, Sun YY, Wu QW, Wang T, Wang PH.

Int J Clin Exp Pathol. 2013 Nov 15;6(12):2745-56. eCollection 2013.

3.

Activation of AKT/ERK confers non-small cell lung cancer cells resistance to vinorelbine.

Fan DP, Zhang YM, Hu XC, Li JJ, Zhang W.

Int J Clin Exp Pathol. 2013 Dec 15;7(1):134-43. eCollection 2014.

4.

RNA-seq reveals determinants of sensitivity to chemotherapy drugs in esophageal carcinoma cells.

Yang LX, Li BL, Liu XH, Yuan Y, Lu CJ, Chen R, Zhao J.

Int J Clin Exp Pathol. 2014 Mar 15;7(4):1524-33. eCollection 2014.

5.

Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.

Sugimura M, Sagae S, Ishioka S, Nishioka Y, Tsukada K, Kudo R.

Oncology. 2004;66(1):53-61.

PMID:
15031599
6.

Gene and microRNA expression reveals sensitivity to paclitaxel in laryngeal cancer cell line.

Xu CZ, Xie J, Jin B, Chen XW, Sun ZF, Wang BX, Dong P.

Int J Clin Exp Pathol. 2013 Jun 15;6(7):1351-61. Print 2013.

7.

Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells.

Wu XM, Shao XQ, Meng XX, Zhang XN, Zhu L, Liu SX, Lin J, Xiao HS.

Acta Pharmacol Sin. 2011 Feb;32(2):259-69. doi: 10.1038/aps.2010.204.

8.

Establishment of new intraperitoneal paclitaxel-resistant gastric cancer cell lines and comprehensive gene expression analysis.

Murakami H, Ito S, Tanaka H, Kondo E, Kodera Y, Nakanishi H.

Anticancer Res. 2013 Oct;33(10):4299-307.

PMID:
24122996
9.

Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells.

Liu SQ, Yu JP, Yu HG, Lv P, Chen HL.

Dig Liver Dis. 2006 May;38(5):310-8. Epub 2006 Mar 9.

PMID:
16527552
10.

Paclitaxel/tetrandrine coloaded nanoparticles effectively promote the apoptosis of gastric cancer cells based on "oxidation therapy".

Li X, Lu X, Xu H, Zhu Z, Yin H, Qian X, Li R, Jiang X, Liu B.

Mol Pharm. 2012 Feb 6;9(2):222-9. doi: 10.1021/mp2002736. Epub 2011 Dec 29.

PMID:
22171565
11.
12.

Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel.

Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P, Liu P.

Cancer Chemother Pharmacol. 2013 May;71(5):1159-71. doi: 10.1007/s00280-013-2108-y. Epub 2013 Feb 20.

PMID:
23423488
13.

Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.

Kim SH, Juhnn YS, Song YS.

Ann N Y Acad Sci. 2007 Jan;1095:82-9.

PMID:
17404021
14.

Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.

Zhang W, Cai J, Chen S, Zheng X, Hu S, Dong W, Lu J, Xing J, Dong Y.

Mol Med Rep. 2015 Jul;12(1):1506-14. doi: 10.3892/mmr.2015.3468. Epub 2015 Mar 11.

PMID:
25760096
15.

Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.

Ho CM, Huang CJ, Huang SH, Chang SF, Cheng WF.

BMC Cancer. 2015 Oct 24;15:789. doi: 10.1186/s12885-015-1744-5.

16.

Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.

Huh JH, Kim TH, Kim K, Song JA, Jung YJ, Jeong JY, Lee MJ, Kim YK, Lee DH, An HJ.

Br J Cancer. 2013 Jul 23;109(2):452-61. doi: 10.1038/bjc.2013.305. Epub 2013 Jun 27.

17.

Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.

Yang YI, Lee KT, Park HJ, Kim TJ, Choi YS, Shih IeM, Choi JH.

Carcinogenesis. 2012 Dec;33(12):2488-98. doi: 10.1093/carcin/bgs302. Epub 2012 Oct 1.

PMID:
23027625
18.

Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.

Wang S, Huang X, Lee CK, Liu B.

Oncogene. 2010 Jul 22;29(29):4225-36. doi: 10.1038/onc.2010.180. Epub 2010 May 24.

PMID:
20498641
19.

Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.

Jeong JY, Kim KS, Moon JS, Song JA, Choi SH, Kim KI, Kim TH, An HJ.

Apoptosis. 2013 Apr;18(4):509-20. doi: 10.1007/s10495-013-0807-9.

20.

ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells.

Suyama H, Igishi T, Sano H, Matsumoto S, Shigeoka Y, Nakanishi H, Endo M, Burioka N, Hitsuda Y, Shimizu E.

Int J Oncol. 2004 Jun;24(6):1499-504.

PMID:
15138593

Supplemental Content

Support Center